Calypso Enters into Agreement to Be Acquired by Novartis
Calypso is a European biotech translating Interleukin-15 biology into medical breakthroughs by developing CALY-002, an anti-IL-15 monoclonal antibody, for an array of autoimmuneindications
January 8, 2024
by B3C newswire
Domestic New Drug R&D Strength is Gradually Ascending, and Overseas Product Authorization is in Full Swing
On November 13th, LEGN.US reached an 1 billion US dollar cooperation agreement with Novartis Pharmaceuticals.
December 14, 2023
by WND/PharmaSources
Maxion Therapeutics Awarded £2 Million Innovate UK Funding to Develop Ion Channel Antibodies for “Hard-To-Treat" Autoimmune Diseases
Maxion therapeutics awarded £2 million Innovate UK funding to develop ion channel antibodies for “Hard-To-Treat" autoimmune diseases.
April 20, 2023
by PharmaSources
serYmun Yeast Announces Preclinical Safety and Efficacy Data for Their Yeast-Based Vaccine Against Porcine Parvovirus (PPV)
an animal health vaccine development company based in Germany, announces the breakthrough in the development of their first pig vaccine candidate against porcine parvovirus.
March 6, 2023
by PharmaSources
COVID Infection May Boost Antibodies for Up to 20 Months
If you've already had COVID-19, your natural antibodies may last as long as 20 months, a new study suggests.
February 7, 2022
by drugs.com
Anti-RBD Antibodies Detected Up to 20 Months After COVID-19
Anti-receptor binding domain (RBD) antibodies are detected in 99 percent of unvaccinated individuals...
February 7, 2022
by drugs.com
HanBio Therapeutics Announces the Completion of a US$40 Million Series A Financing Led by OrbiMed and Hankang Capital
HanBio Therapeutics ("HanBio"), a biotechnology company committed to researching and developing next generation transformative medicines, today announced that it has completed a US$40 million Series...
January 29, 2022
by prnasia
MU study identifies mutations specific to Omicron variant
While the Omicron variant continues to infect people around the world, researchers at the University of Missouri have identified the highly prevalent, specific mutations that are causing the Omicron variant's high rate of infection.
January 24, 2022
by FirstWordPharma
Fourth COVID vaccine partially effective against Omicron: Israeli study
A fourth dose of COVID-19 vaccine boosts antibodies to higher levels than the third jab but provides only partial protection against the Omicron variant of coronavirus, according to a preliminary study conducted in Israel.
January 20, 2022
by ExpressPharma
Global COVID-19 Therapeutics Market worth $14.6 billion by 2022 - Exclusive Report by InsightAce Analytic
The newly published report titled "Global COVID-19 Therapeutics Market– By Trends, Industry Competition Analysis, Clinical Trial/Pipeline Analysis, Revenue (US$ Billions) and Forecast Till 2030." of InsightAce...
January 19, 2022
by prnewswire
Prellis, Bristol Myers Squibb collaborate to discover antibodies
Prellis Biologics and Bristol Myers Squibb have signed a multi-target collaboration and license agreement to discover antibodies.
January 14, 2022
by pharmaceutical-business-review
COVID-19 can trigger self-attacking antibodies
Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild symptoms or no symptoms at all...
January 4, 2022
by WorldPharmaNews